TDMS Study 05103-05 Pathology Tables
INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)
2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL
NTP Experiment-Test: 05103-05 Report: PEIRPT05
Study Type: CHRONIC Date: 05/19/95
Route: DOSED FEED Time: 19:49:13
Facility: Southern Research Institute
Chemical CAS #: 3296-90-0
Lock Date: 02/18/92
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05103-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL Date: 05/19/95
Route: DOSED FEED Time: 19:49:13
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE UNTREATD 0.25% 0.50% 1.00%
CONTROL
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 60 60
Scheduled Sacrifice 10 9 7 8
Early Deaths
Moribund Sacrifice 14 22 27 41
Natural Death 2 3 6
Survivors
Terminal Sacrifice 36 27 23 5
Animals Examined Microscopically 60 60 60 60
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (60) (60) (60) (60)
Squamous Cell Papilloma 1 (2%) 10 (17%)
Intestine Large, Colon (60) (60) (60) (60)
Polyp Adenomatous 1 (2%)
Intestine Large, Cecum (60) (60) (60) (60)
Histiocytic Sarcoma 1 (2%)
Intestine Small, Jejunum (60) (60) (60) (60)
Carcinoma 1 (2%)
Intestine Small, Ileum (60) (59) (60) (60)
Liver (60) (60) (60) (60)
Carcinoma, Multiple, Metastatic, Islets,
Pancreatic 1 (2%)
Mesentery (6) (12) (9) (6)
Histiocytic Sarcoma 1 (17%)
Pancreas (60) (60) (60) (60)
Histiocytic Sarcoma 1 (2%)
Pharynx (1) (1) (1) (2)
Palate, Squamous Cell Carcinoma 1 (100%) 1 (100%)
Palate, Squamous Cell Papilloma 1 (100%) 1 (50%)
Salivary Glands (60) (60) (60) (60)
Histiocytic Sarcoma 1 (2%)
Stomach, Forestomach (60) (60) (60) (60)
Squamous Cell Papilloma 1 (2%)
Stomach, Glandular (60) (60) (60) (60)
Histiocytic Sarcoma 1 (2%)
Tongue (1) (3) (6) (6)
Squamous Cell Carcinoma 1 (17%)
Squamous Cell Papilloma 1 (100%) 2 (67%) 4 (67%) 4 (67%)
____________________________________________________________________________________________________________________________________
Page 2
NTP Experiment-Test: 05103-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL Date: 05/19/95
Route: DOSED FEED Time: 19:49:13
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE UNTREATD 0.25% 0.50% 1.00%
CONTROL
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (59) (60) (60) (60)
Pericardium, Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (60) (60) (60) (60)
Adenoma 1 (2%)
Adrenal Medulla (60) (60) (60) (60)
Pheochromocytoma Complex 1 (2%)
Pheochromocytoma Benign 1 (2%) 1 (2%) 1 (2%)
Islets, Pancreatic (60) (60) (60) (60)
Adenoma 2 (3%) 1 (2%)
Carcinoma 1 (2%)
Pituitary Gland (58) (60) (59) (59)
Pars Distalis, Adenoma 16 (28%) 24 (40%) 24 (41%) 16 (27%)
Thyroid Gland (60) (60) (60) (60)
Histiocytic Sarcoma 1 (2%)
C-Cell, Adenoma 6 (10%) 5 (8%) 7 (12%) 4 (7%)
C-Cell, Carcinoma 2 (3%) 3 (5%)
Follicular Cell, Adenoma 2 (3%) 4 (7%)
Follicular Cell, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (58) (58) (56) (60)
Adenoma 3 (5%) 3 (5%) 7 (13%) 3 (5%)
Carcinoma 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%)
Bilateral, Adenoma 1 (2%)
Ovary (60) (60) (60) (60)
Granulosa Cell Tumor Benign 1 (2%) 1 (2%)
Uterus (60) (60) (60) (60)
Endometrium, Adenoma 1 (2%)
Endometrium, Carcinoma 1 (2%)
Endometrium, Polyp Stromal 4 (7%) 8 (13%) 7 (12%) 6 (10%)
Endometrium, Polyp Stromal, Multiple 1 (2%) 1 (2%)
Endometrium, Sarcoma Stromal 1 (2%)
____________________________________________________________________________________________________________________________________
Page 3
NTP Experiment-Test: 05103-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL Date: 05/19/95
Route: DOSED FEED Time: 19:49:13
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE UNTREATD 0.25% 0.50% 1.00%
CONTROL
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (60) (60) (60) (60)
Lymph Node (16) (11) (15) (19)
Histiocytic Sarcoma 1 (6%)
Inguinal, Histiocytic Sarcoma 1 (6%)
Lymph Node, Mandibular (59) (57) (60) (58)
Histiocytic Sarcoma 1 (2%)
Lymph Node, Mesenteric (60) (60) (60) (60)
Spleen (60) (60) (60) (60)
Hemangiosarcoma 1 (2%) 1 (2%)
Thymus (59) (59) (58) (60)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (60) (60) (60) (60)
Adenoma 2 (3%)
Carcinoma 3 (5%) 4 (7%) 3 (5%) 4 (7%)
Carcinoma, Multiple 1 (2%)
Fibroadenoma 20 (33%) 9 (15%) 6 (10%) 9 (15%)
Fibroadenoma, Multiple 6 (10%) 37 (62%) 40 (67%) 39 (65%)
Skin (60) (60) (60) (60)
Keratoacanthoma 2 (3%)
Squamous Cell Carcinoma 1 (2%)
Squamous Cell Papilloma 3 (5%) 1 (2%)
Trichoepithelioma 1 (2%)
Subcutaneous Tissue, Fibroma 1 (2%) 4 (7%) 1 (2%) 2 (3%)
Subcutaneous Tissue, Fibrosarcoma 2 (3%)
Subcutaneous Tissue, Histiocytic Sarcoma 1 (2%)
Subcutaneous Tissue, Lipoma 2 (3%)
Subcutaneous Tissue, Sarcoma 1 (2%) 2 (3%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (1) (1) (1)
Histiocytic Sarcoma 1 (100%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (59) (60) (60) (60)
Astrocytoma NOS 1 (2%) 1 (2%)
Oligodendroglioma NOS 1 (2%)
____________________________________________________________________________________________________________________________________
Page 4
NTP Experiment-Test: 05103-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL Date: 05/19/95
Route: DOSED FEED Time: 19:49:13
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE UNTREATD 0.25% 0.50% 1.00%
CONTROL
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (60) (60) (60) (60)
Alveolar/Bronchiolar Adenoma 1 (2%)
Alveolar/Bronchiolar Carcinoma 1 (2%) 2 (3%)
Carcinoma, Multiple, Metastatic, Islets,
Pancreatic 1 (2%)
Histiocytic Sarcoma 1 (2%)
Mediastinum, Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Zymbal's Gland (2) (2) (1)
Adenoma 1 (50%)
Carcinoma 2 (100%) 1 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (60) (60) (60) (60)
Stromal Nephroma 1 (2%)
Renal Tubule, Adenoma 1 (2%)
Urinary Bladder (60) (60) (60) (60)
Histiocytic Sarcoma 1 (2%)
Transitional Epithelium, Papilloma 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(60) *(60) *(60) *(60)
Histiocytic Sarcoma 1 (2%)
Leukemia Mononuclear 15 (25%) 13 (22%) 19 (32%) 19 (32%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 5
NTP Experiment-Test: 05103-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL Date: 05/19/95
Route: DOSED FEED Time: 19:49:13
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE UNTREATD 0.25% 0.50% 1.00%
CONTROL
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 46 52 56 57
Total Primary Neoplasms 93 127 135 138
Total Animals with Benign Neoplasms 41 50 52 53
Total Benign Neoplasms 66 103 106 102
Total Animals with Malignant Neoplasms 21 22 27 31
Total Malignant Neoplasms 26 24 28 35
Total Animals with Metastatic Neoplasms 1
Total Metastatic Neoplasm 2
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant 1 1 1
Total Uncertain Neoplasms 1 1 1
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 6
NTP Experiment-Test: 05103-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL Date: 05/19/95
Route: DOSED FEED Time: 19:49:13
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE UNTREATD 0.25% 0.50% 1.00% 2.00%
CONTROL
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 70 60 60 60 70
Scheduled Sacrifice 19 7 9 5 10
Early Deaths
Moribund Sacrifice 24 30 36 43 55
Natural Death 1 3 2 11 5
Survivors
Terminal Sacrifice 26 20 13 1
Animals Examined Microscopically 70 60 60 60 70
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (70) (60) (60) (60) (70)
Squamous Cell Carcinoma 1 (2%)
Squamous Cell Papilloma 1 (2%) 5 (8%)
Intestine Large, Colon (70) (59) (60) (59) (69)
Carcinoma 1 (1%)
Carcinoma, Multiple 1 (1%)
Hemangioma 1 (2%)
Leiomyoma 1 (2%)
Leiomyosarcoma 1 (2%)
Polyp Adenomatous 3 (5%) 4 (7%) 8 (12%)
Polyp Adenomatous, Multiple 1 (1%)
Intestine Large, Rectum (70) (59) (59) (58) (69)
Polyp Adenomatous 1 (1%)
Intestine Large, Cecum (70) (59) (60) (59) (69)
Intestine Small, Duodenum (70) (60) (60) (57) (69)
Squamous Cell Carcinoma, Metastatic, Lung 1 (1%)
Intestine Small, Jejunum (70) (59) (60) (58) (69)
Carcinoma 2 (3%) 2 (3%)
Polyp Adenomatous 1 (1%)
Intestine Small, Ileum (70) (59) (60) (58) (69)
Carcinoma 1 (1%)
Squamous Cell Carcinoma, Metastatic, Lung 1 (1%)
Mucosa, Carcinoma 1 (1%)
Liver (70) (60) (60) (60) (70)
Hepatocellular Carcinoma 1 (1%)
Hepatocellular Adenoma 1 (2%)
Hepatocellular Adenoma, Multiple 1 (2%)
Sarcoma 1 (2%)
Sarcoma, Metastatic, Spleen 1 (2%)
Mesentery (16) (20) (21) (23) (30)
Carcinoma, Metastatic, Seminal Vesicle 1 (3%)
Page 7
NTP Experiment-Test: 05103-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL Date: 05/19/95
Route: DOSED FEED Time: 19:49:13
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE UNTREATD 0.25% 0.50% 1.00% 2.00%
CONTROL
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Fibroma 1 (5%)
Hemangiosarcoma 1 (5%)
Sarcoma 2 (9%)
Pancreas (70) (60) (60) (58) (69)
Sarcoma 1 (2%)
Squamous Cell Carcinoma, Metastatic, Lung 1 (1%)
Acinar Cell, Adenoma 1 (1%) 2 (3%) 4 (7%) 2 (3%) 2 (3%)
Acinar Cell, Adenoma, Multiple 1 (2%) 1 (1%)
Pharynx (1) (3) (4) (5) (10)
Palate, Squamous Cell Carcinoma 2 (20%)
Palate, Squamous Cell Papilloma 2 (67%) 3 (75%) 2 (40%) 7 (70%)
Salivary Glands (70) (59) (58) (60) (70)
Stomach, Forestomach (70) (60) (60) (60) (69)
Sarcoma 1 (2%)
Squamous Cell Papilloma 1 (2%) 4 (6%)
Mucosa, Squamous Cell Papilloma 1 (1%)
Stomach, Glandular (70) (60) (60) (58) (70)
Sarcoma 1 (2%)
Tongue (2) (5) (13) (9)
Squamous Cell Papilloma 2 (100%) 5 (100%) 8 (62%) 5 (56%)
Squamous Cell Papilloma, Multiple 1 (11%)
Tooth (1) (1) (2)
Gingiva, Squamous Cell Carcinoma 1 (100%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (69) (60) (60) (60) (70)
Carcinoma, Metastatic, Seminal Vesicle 1 (1%)
Schwannoma NOS 1 (1%) 1 (2%) 1 (2%)
Squamous Cell Carcinoma, Metastatic, Lung 1 (1%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (70) (60) (60) (59) (70)
Adenoma 1 (1%) 1 (2%) 1 (2%)
Squamous Cell Carcinoma, Metastatic, Lung 1 (1%)
Adrenal Medulla (70) (60) (60) (59) (70)
Pheochromocytoma Malignant 3 (4%) 3 (5%) 1 (2%) 1 (2%)
Pheochromocytoma Complex 1 (2%)
Pheochromocytoma Benign 6 (9%) 9 (15%) 4 (7%) 4 (7%)
Bilateral, Pheochromocytoma Benign 1 (1%) 3 (5%)
Islets, Pancreatic (70) (60) (60) (60) (69)
Adenoma 1 (1%) 6 (10%) 1 (2%)
Carcinoma 2 (3%) 1 (2%)
Parathyroid Gland (68) (57) (58) (58) (68)
Page 8
NTP Experiment-Test: 05103-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL Date: 05/19/95
Route: DOSED FEED Time: 19:49:13
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE UNTREATD 0.25% 0.50% 1.00% 2.00%
CONTROL
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - cont
Pituitary Gland (69) (58) (59) (58) (67)
Pars Distalis, Adenoma 9 (13%) 10 (17%) 6 (10%) 6 (10%) 5 (7%)
Pars Distalis, Carcinoma 1 (2%)
Pars Intermedia, Adenoma 1 (1%) 1 (1%)
Thyroid Gland (70) (60) (60) (60) (69)
Bilateral, C-Cell, Carcinoma 1 (2%)
C-Cell, Adenoma 7 (10%) 5 (8%) 4 (7%) 4 (7%) 4 (6%)
C-Cell, Carcinoma 1 (1%) 1 (2%) 1 (2%) 2 (3%)
Follicular Cell, Adenoma 1 (2%) 2 (3%) 2 (3%) 7 (10%)
Follicular Cell, Carcinoma 1 (2%) 4 (7%) 1 (2%) 2 (3%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (1) (2) (3) (6) (8)
Pelvic, Chordoma 1 (17%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (70) (60) (60) (59) (70)
Penis (1)
Sarcoma 1 (100%)
Preputial Gland (70) (59) (60) (60) (70)
Adenoma 3 (4%) 3 (5%) 4 (7%) 4 (7%) 4 (6%)
Carcinoma 2 (3%) 1 (2%) 1 (2%) 1 (2%)
Duct, Squamous Cell Papilloma 1 (1%)
Prostate (70) (60) (60) (60) (70)
Carcinoma, Metastatic, Seminal Vesicle 1 (1%)
Seminal Vesicle (70) (60) (60) (60) (70)
Adenoma 1 (1%)
Carcinoma 1 (1%)
Testes (70) (60) (60) (60) (70)
Bilateral, Interstitial Cell, Adenoma 52 (74%) 50 (83%) 56 (93%) 52 (87%) 52 (74%)
Interstitial Cell, Adenoma 5 (7%) 4 (7%) 4 (7%) 4 (7%) 7 (10%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (70) (60) (60) (60) (70)
Lymph Node (25) (23) (36) (27) (31)
Deep Cervical, Carcinoma, Metastatic,
Thyroid Gland 1 (3%)
Lymph Node, Mandibular (68) (59) (58) (60) (69)
Lymph Node, Mesenteric (69) (60) (60) (60) (70)
Spleen (70) (60) (60) (59) (70)
Carcinoma, Metastatic, Seminal Vesicle 1 (1%)
Page 9
NTP Experiment-Test: 05103-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL Date: 05/19/95
Route: DOSED FEED Time: 19:49:13
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE UNTREATD 0.25% 0.50% 1.00% 2.00%
CONTROL
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Fibroma 1 (2%)
Sarcoma 1 (1%) 1 (2%)
Thymus (67) (60) (58) (57) (67)
Epithelial Cell, Thymoma Malignant 1 (2%)
Epithelial Cell, Thymoma NOS 1 (1%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (66) (58) (57) (53) (60)
Adenoma 1 (2%) 1 (2%)
Fibroadenoma 3 (5%) 4 (7%) 6 (11%) 4 (7%)
Fibroadenoma, Multiple 1 (2%) 2 (4%) 1 (2%)
Skin (70) (60) (60) (59) (69)
Basal Cell Adenoma 1 (2%) 3 (5%) 6 (9%)
Basal Cell Carcinoma 2 (3%) 2 (3%)
Carcinoma, Metastatic, Zymbal's Gland 1 (2%)
Keratoacanthoma 2 (3%) 5 (8%) 9 (15%) 16 (27%) 9 (13%)
Keratoacanthoma, Multiple 1 (1%) 2 (3%) 1 (1%)
Squamous Cell Carcinoma 1 (1%)
Squamous Cell Papilloma 1 (1%) 1 (2%) 2 (3%) 5 (8%) 10 (14%)
Squamous Cell Papilloma, Multiple 1 (2%) 1 (1%)
Trichoepithelioma 1 (2%) 1 (1%)
Pinna, Melanoma Malignant 1 (2%)
Sebaceous Gland, Adenoma 1 (2%) 2 (3%) 2 (3%)
Subcutaneous Tissue, Carcinoma, Metastatic,
Thyroid Gland 1 (2%)
Subcutaneous Tissue, Fibroma 2 (3%) 8 (13%) 7 (12%) 9 (15%) 7 (10%)
Subcutaneous Tissue, Fibroma, Multiple 4 (7%) 6 (10%)
Subcutaneous Tissue, Fibrosarcoma 1 (2%) 1 (1%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%)
Subcutaneous Tissue, Lipoma 1 (2%)
Subcutaneous Tissue, Sarcoma 2 (3%) 2 (3%) 2 (3%)
Subcutaneous Tissue, Sarcoma, Multiple 1 (2%)
Subcutaneous Tissue, Schwannoma Malignant 2 (3%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (70) (60) (60) (60) (70)
Osteosarcoma 1 (1%)
Skeletal Muscle (3) (2) (4) (4)
Hemangiosarcoma 1 (25%)
Squamous Cell Carcinoma, Metastatic, Lung 1 (25%)
Thymoma Malignant, Metastatic 1 (25%)
____________________________________________________________________________________________________________________________________
Page 10
NTP Experiment-Test: 05103-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL Date: 05/19/95
Route: DOSED FEED Time: 19:49:13
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE UNTREATD 0.25% 0.50% 1.00% 2.00%
CONTROL
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (70) (60) (60) (60) (70)
Astrocytoma NOS 1 (2%)
Carcinoma, Metastatic, Pituitary Gland 1 (2%)
Oligodendroglioma NOS 1 (2%)
Squamous Cell Carcinoma, Metastatic, Lung 1 (1%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (70) (60) (60) (60) (70)
Alveolar/Bronchiolar Adenoma 1 (1%) 3 (5%) 1 (2%) 4 (6%)
Alveolar/Bronchiolar Carcinoma 1 (2%) 2 (3%) 2 (3%)
Alveolar/Bronchiolar Carcinoma, Multiple 1 (2%) 1 (1%)
Carcinoma, Multiple, Metastatic, Seminal
Vesicle 1 (1%)
Carcinoma, Multiple, Metastatic, Thyroid
Gland 1 (2%)
Carcinoma, Multiple, Metastatic, Zymbal's
Gland 1 (1%)
Carcinoma, Metastatic, Zymbal's Gland 2 (3%) 1 (1%)
Chordoma, Metastatic, Tissue NOS 1 (2%)
Sarcoma 1 (2%)
Sarcoma, Metastatic, Tissue NOS 1 (2%)
Squamous Cell Carcinoma 3 (4%)
Thymoma Malignant, Metastatic, Thymus 1 (2%)
Nose (70) (60) (60) (60) (70)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (2) (1) (3) (1)
Lids, Melanoma NOS 1 (50%) 1 (33%)
Zymbal's Gland (2) (1) (5) (5) (15)
Adenoma 1 (20%) 3 (60%) 2 (13%)
Carcinoma 2 (100%) 1 (100%) 3 (60%) 2 (40%) 13 (87%)
Bilateral, Carcinoma 2 (13%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (70) (60) (60) (60) (69)
Squamous Cell Carcinoma, Metastatic, Lung 1 (1%)
Pelvis, Transitional Epithelium, Carcinoma 1 (2%) 1 (1%)
Renal Tubule, Adenoma 1 (2%) 3 (5%) 1 (1%)
Urinary Bladder (70) (60) (60) (60) (69)
Transitional Epithelium, Carcinoma 1 (2%) 1 (1%)
Page 11
NTP Experiment-Test: 05103-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL Date: 05/19/95
Route: DOSED FEED Time: 19:49:13
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE UNTREATD 0.25% 0.50% 1.00% 2.00%
CONTROL
____________________________________________________________________________________________________________________________________
URINARY SYSTEM - cont
Transitional Epithelium, Papilloma 1 (2%) 3 (5%) 1 (1%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(70) *(60) *(60) *(60) *(70)
Leukemia Mononuclear 28 (40%) 29 (48%) 40 (67%) 34 (57%) 25 (36%)
Mesothelioma Malignant 4 (7%) 9 (15%) 9 (15%) 26 (37%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 12
NTP Experiment-Test: 05103-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL Date: 05/19/95
Route: DOSED FEED Time: 19:49:13
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE UNTREATD 0.25% 0.50% 1.00% 2.00%
CONTROL
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 60 59 60 59 60
Total Primary Neoplasms 135 173 207 237 255
Total Animals with Benign Neoplasms 59 59 60 59 59
Total Benign Neoplasms 95 122 137 161 163
Total Animals with Malignant Neoplasms 33 36 47 50 55
Total Malignant Neoplasms 38 49 67 76 91
Total Animals with Metastatic Neoplasms 1 3 1 6 4
Total Metastatic Neoplasm 1 4 2 8 16
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant 2 2 3 1
Total Uncertain Neoplasms 2 2 3 1
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 13
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------